Menu

Theranos Restructuring with Research Focus

The blood-testing company is shutting down clinical labs, laying off more than 300 employees across three states.

Oct 6, 2016
Tracy Vence

FLICKR, STEVE JURVETSON

Theranos is laying off around 340 employees of clinical labs and “wellness centers” in Arizona, California, and Pennsylvania, Chief Executive Officer Elizabeth Holmes announced yesterday (October 5). This year alone, the company has been investigated by various federal agencies for allegedly misleading officials and operating a lab under substandard conditions; Holmes has been banned from running labs for two years.

In an open letter addressed to the firm’s stakeholders, Holmes yesterday said Theranos would be shifting its focus to research only.

“We will return our undivided attention to our miniLab platform,” Holmes wrote, referring to technology she debuted at the American Association for Clinical Chemistry’s annual meeting in Philadelphia this August. “Our ultimate goal is to commercialize miniaturized, automated laboratories capable of small-volume sample testing, with an emphasis on vulnerable patient populations, including oncology, pediatrics, and intensive care.”

As STAT News reported, “Wednesday’s announcement marks perhaps the most significant retreat for a company that had once been valued at $9 billion, higher than any other venture-backed private company in health care. More recently, Forbes had valued it at $0.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.